Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: A preliminary study

Acta Dermatovenerologica Croatica

Volumn 13, Issue 2, 2005, Pages 97-103

  Szepietowski, Jacek C ^a   Szepietowski, Tomasz ^a   Reich, Adam ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Endocannabinoids; Hemodialysis; Uremic pruritus; Xerosis

Indexed keywords

ACETYLETHANOLAMINE; DERMA MEMBRANE STRUCTURE; ENDOCANNABINOID; LIPID; PALMIDROL; PHYSIOGEL AI; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERANCE; DRY SKIN; FEMALE; HEMODIALYSIS; HUMAN; LIPID COMPOSITION; MALE; PRURITUS; QUESTIONNAIRE; TREATMENT OUTCOME; UREMIA; VISUAL ANALOG SCALE; XEROSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG COMBINATIONS; ENDOCANNABINOIDS; ETHANOLAMINE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PALMITIC ACIDS; PRURITUS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 22444432730     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Szepietowski JC, Sikora M, Kusztal M, Salomon J, Magott M, Szepietowski T. Uraemic pruritus: a clinical study of maintenance haemodialysis patients. J Dermatol 2002;29:621-7.
2. Zucker I, Yosipovitch G, David M, Gafter U, Boner G. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 2003;49:842-6.
3. Urbonas A, Schwartz RA, Szepietowski JC. Uremic pruritus - an update. Am J Nephrol 2001;21:343-50.
4. Szepietowski JC, Schwartz RA. Uremic pruritus. Int J Dermatol 1998;37:247-53.
5. Vacata V, Grtchen-Ohlinschläger B, Ghyczy M. Topical formulations conforming to the structure of the skin. Cosmetics Toiletries 2001;116:67-74.
6. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC, et al. Itch: scratching more than the surface. Q J Med 2003;96:7-26.
7. Brüning H, Knaussmann HG, Rüther TH, Ude P. Physiogel® cream - a new base therapy for patients with neurodermatitis. Hautnah Schweiz 2002;1:35-8.
8. Szepietowski J, Salomon J. Physiogel® cream: therapeutic effects of the treatment of dry skin. Dermatol Estet 2003;5:195-9.
9. Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 2002;9:663-74.
10. Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Rossi A, Finazzi-Agro A. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activating protein-1 and transglutamidase. J Biol Chem 2003;278:33896-903.
11. Rukwied R, Dvorak M, Watkinson A, McGlone F. Putative role of cannabinoids in experimentally induced itch and inflammation in human skin. In: Yosipovitch G, Greaves MW, Fleischer AB Jr, McGlone F, editors. Itch: basic mechanisms and therapy. New York: Marcel Dekker Inc; 2004. p. 115-30.
12. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995;92:3376-80.
13. Mazzari S, Canela R, Petrelli L Marcolongo G, Leon A. N-(2-hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 1996;300:227-36.
14. Berdyschev EV, Boichot E, Corbel M, Germain N, Lagente V. Influence of fatty acid ethanolamides and delta 9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 1997;330:231-40.
15. Berdyshev EV, Boichot E, Corbel M, Germain N, Lagente V. Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci 1998;63:PL 125-29.
16. Costa B, Conti S, Giagnoni G, Colleoni M. Therapeutic effect of the endogenous acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol 2002;137:413-20.
17. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998;76:189-99.
18. Scarampella F, Abramo F, Noli C. Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Vet Dermatol 2001;12:29-39.
19. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 2002;135:181-7.
20. Szepietowski J, Thepen T, van Vloten WA, Szepietowski T, Bihari IC. Pruritus and mast cell proliferation in the skin of haemodialysis patients. Inflamm Res 1995;44 (Suppl 1):S84-S85.
21. Szepietowski J. Selected elements of the pathogenesis of pruritus in haemodialysis patients: the own study. Med Sci Monit 1996;2:343-7.
22. Matsumoto M, Ichimaru K, Hohe A. Pruritus and mast cell proliferation of the skin in end stage renal failure. Clin Nephrol 1985;23:285-8.
23. Leong SO, Tan CC, Lye WC, Lee EJ, Chan HL. Dermal mast cell density and pruritus in the end stage renal failure. Ann Acad Med Singapore 1994;23:327-9.